Biotec Pharmacon finalises Post Market study on Woulgan®

Tromsø, Norway, 29 January 2019 – Biotec Pharmacon's (OSE: Biotec) has announced that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in diabetic foot ulcer patients.

Biotec BetaGlucans filed an application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in June 2018 to finalise the study. The application was accepted in November 2018 and all patients have now been treated.

The study, initiated in 2015, was part of the MHRA’s requirements to assess the safety and usefulness of Woulgan® before approval as a medical device in the management of wounds. The study aimed to recruit 60 patients for treatment with Woulgan® gel and 20 with a commercial hydrogel from Smith & Nephew (Intrasite®). The study was allowed to be finalised after having recruited just above 60 patients in total.

In parallel with this study, Biotec Pharmacon ran a large 300-patient clinical study in the UK (including diabetic patients), demonstrating the Woulgan® gel’s excellent safety profile and its clinical efficacy and usability. This evidence, alongside case studies, has contributed to the MHRA’s favourable decision to allow the completion of the PMCF study.

The Contract Research Organisation handling the study is now collecting and evaluating the data from the four clinical investigation sites. The results are expected in late Q2 2019.

Christian Jørgensen, CEO, said:  

“The acceptance from the MHRA and study completion is a positive step forwards for the Company. These results expected mid-year will provide further validation of our Woulgan® gel product in wound care management.”


For more information, please contact:

Biotec   Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Instinctif   Partners
Melanie Toyne-Sewell / Dr Christelle Kerouedan / Deborah Bell Tel: +44 207 457 2020

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website:

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit:


Documents & Links